The IMF’s Understanding series of cancer information booklets is designed to acquaint you with specific multiple myeloma-related tests, treatments and therapies, supportive care measures, and common adverse events.

Due to current health and safety precautions, hard copy mailing of IMF publications are temporarily delayed up to several weeks. However, digital versions of all IMF publications are available below.

Order Print Edition


This publication discusses the use of Revlimid (lenalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
The Understanding SARCLISA® (isatuximab-irfc) booklet discusses a novel anti-CD38 monoclonal antibody that is approved for patients with relapsed and…
This publication discusses the use of Thalomid (Thalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
This publication discusses the effects of myeloma on the immune system.
The Understanding the VRd Regimen booklet discusses a combination therapy for treating newly diagnosed myeloma that consists of three drugs

We Thank Our Sponsors:
Amgen, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Karyopharm, Sanofi, and Takeda Oncology

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.